African Development Bank Backs South Africa’s Bid to Become a Global Vaccine Manufacturing Power

$15 million investment in Biovac aims to transform Africa from a vaccine importer into a leading producer while creating hundreds of skilled jobs

Africa’s ambition to become a global force in vaccine manufacturing has received a major boost after the African Development Bank Group confirmed a financing agreement of up to $15 million with South African biotechnology company Biovac.

The investment will fund the construction of a new multi-vaccine manufacturing facility in Cape Town, significantly expanding domestic production capacity and positioning South Africa at the centre of Africa’s growing pharmaceutical industry.

Once operational, the facility is expected to increase Biovac’s annual manufacturing capacity to 500 million vaccine doses, helping reduce the continent’s overwhelming dependence on imported vaccines while supporting international efforts to improve health security.

The project represents one of the most significant investments in African vaccine production in recent years and is expected to strengthen regional supply chains, boost exports and support economic development alongside improved healthcare outcomes.

Tackling Africa’s vaccine dependence

Despite carrying a substantial share of the world’s vaccine-preventable diseases, Africa currently imports more than 99% of the vaccines it uses.

The African Union has set an ambitious target of producing 60% of the continent’s vaccines locally by 2040, with projects such as Biovac’s expansion viewed as critical to achieving that goal.

The new Cape Town facility will make Biovac the continent’s first end-to-end manufacturer of oral cholera vaccines while also becoming South Africa’s first producer of locally manufactured inactivated polio vaccines.

Production will be delivered through technology-transfer partnerships with Sanofi, the International Vaccine Institute, Biological E Limited, EuBiologics and Bharat Biotech, creating one of Africa’s most advanced vaccine manufacturing operations.

Initially the plant will manufacture oral cholera vaccines before expanding production to include vaccines protecting against polio, pneumonia and meningitis.

Construction is expected to be completed in 2028.

Hundreds of skilled jobs

Alongside expanding pharmaceutical production, the project is forecast to generate around 340 full-time jobs, with approximately 43% of positions expected to be filled by women and 30% by young people.

Biovac, which already employs more than 300 people, also plans to increase specialist training programmes covering vaccine manufacturing, quality assurance and regulatory science through partnerships with South African universities and regional educational institutions.

The initiative is expected to strengthen Africa’s pharmaceutical skills base while helping establish long-term industrial capability across the continent.

Building Africa’s health sovereignty

Solomon Quaynor, the African Development Bank Group’s Vice President for Private Sector, Infrastructure, and Industrialisation, said:

“This investment in Biovac is about much more than expanding vaccine production capacity. It is about building Africa’s health sovereignty, strengthening regional value chains, and creating industrial capabilities that will enable the continent to respond more effectively to future health emergencies.

“By supporting Africa’s first end-to-end oral cholera vaccine manufacturing facility and the continent’s first local production of inactivated polio vaccine, we are helping transform Africa from a consumer of imported vaccines into a producer of critical health solutions.”

Biovac Chief Executive Officer Morena Makhoana described the investment as a landmark moment for African healthcare manufacturing.

“We welcome the African Development Bank as a partner in this landmark project and are proud that an institution so central to Africa’s development sees in Biovac the same opportunity we see, a chance to fundamentally shift the continent’s relationship with its own health security.

“The project will shift the narrative from majority-imported vaccines to majority-exported vaccines. This is part of changing that reality permanently. This is what Africa’s health sovereignty looks like in practice, and we are honoured to be building it.”

International backing for vaccine production

The African Development Bank joins an international consortium of development finance institutions supporting the project.

The funding package is led by the International Finance Corporation (IFC) and includes long-term quasi-equity financing through the Human Development Accelerator (HDX) programme, a European Union-backed initiative delivered by the European Investment Bank in partnership with the Gates Foundation.

Additional grant funding and technical support will assist technology transfers that expand Biovac’s vaccine portfolio.

The project is also expected to benefit from Gavi’s African Vaccine Manufacturing Accelerator (AVMA), a $1.2 billion programme designed to encourage African vaccine production by rewarding manufacturers once they achieve World Health Organization prequalification and supply vaccines through UNICEF procurement programmes.

Strengthening Africa’s pharmaceutical future

Kennedy Mbekeani, the African Development Bank Group’s Director General for Southern Africa and Country Manager for South Africa, said:

“This project allows one of Africa’s most experienced manufacturers to scale up exactly where the need is greatest: vaccines that protect children from cholera, polio, pneumonia and meningitis.”

Founded in 2003 in partnership with the South African government, Biovac has supplied more than 450 million vaccine doses across Southern Africa, including COVID-19 vaccines.

As governments worldwide seek more resilient pharmaceutical supply chains following the lessons of the COVID-19 pandemic, the Cape Town expansion is expected to play an increasingly important role in both African healthcare resilience and the continent’s emergence as a globally significant vaccine manufacturing hub.

—

Stock Image: Magnific

About Editor 4283 Articles
Lisa Baker is the Editor of International Business News. As the Owner of Need to See IT Publishing, Lisa is an experienced business and technology journalist and publisher.